DOCSLIB.ORG

Pseudomonas Aeruginosa

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Pseudomonas Aeruginosa Extending the Spectrum of Pleuromutilins to MDR Gram-negatives 28th ECCMID April 24, 2018 Michio Kurosu, Professor College of Pharmacy University of Tennessee Health Science Center ESCMIDMemphis, eLibrary TN https://mkurosu2.wixsite.com/kurosulab© by author Antibiotic Resistance Threats Antibiotic Resistance Antibiotic Identified Introduced ESKAPE pathogens Penicillin-R Staohylococcus 1940 1943 Penicillin CDC assessment (7 factors) Urgent threats Clostridium difficile 1950 Tetracycline Carbapenem-resitstant Enterobacteriaciacease 1953 Erythromycin Drug-resistant Neisseria gonorrhoeae Serious Threats Tetracycline-R Shigella 1959 1960 Methicillin MDR-Acinetobacter baumannii Methicillin-R Staphylococcus 1962 MDR-Pseudomonas aeruginosa Penicillin-R Pneumococcus 1965 1967 Gentamicin MDR-Mycobacterium tuberculosis plus 10 others (1 fungus) 1972 Vancomycin Concerning Threats (3 bacteria) Gentamicin-R Pneumococcus 1979 Number of Antibacterial Approval 19 1985 Imipenem and 20 Ceftazidime-R Enterobacteriaceae 1987 Ceftazidime Vancomycin-R Enterococcus 1988 18 16 Levofloxacin-R Pneumococcus 1996 1996 Levofloxacin 14 11 XDR Tuberculosis 2000 2000 Linezolid 12 Linezolid-R Staphylococcus 2001 10 Vancomycin-R Staphylococcus 2002 2003 Daptomycin 8 6 MDR Acinetobacter and Pseudomonas 2004 6 4 3 Ceftriaxone-R Neisseria 2009 2010 Ceftaroline 4 MDR Enterobacteriaceae 2009 2012 Bedaquline (TB) 2 Cetaroline-R Staphylococcus 2011 ESCMID2014 eLibraryDalbancin (iv) 0 Tedizolid 1980- 1995- 2000- 2005- 2010- Cefdtobiprole (USA) 1984 1999 2004 2009 2014 Ceflozane-tazobactam (iv) Fewer options to treat © by2015 Ceftazidime author-avibactam resistant bacteria Development of New Antimicrobial Agents Objective • A significant public health problem: the increasing multidrug resistance (MDR) among Gram-negative bacteria (Klebsiella pneumoniae, Acinetobacter baumanii, Pseudomonas aeruginosa, and Enterobacteriaceae) Gram-positive bacteria (Spore-forming bacteria), Mycobacterium tuberculosis Challenges • New antibiotic profiles: effective against sensitive strains, safe • New antibiotics must not only be active against resistant strains but must outperform the products already marketed against sensitive strains • The results of over 10 years’ screening of strains and molecular targets from traditional sources (randomly generated library molecules, and secondary metabolites) have been disappointing (no drug leads have been identified against new targets) Strategy for the development of new drug leads for MDR bacteria • Essential and unexploited bacterial drug target(s) • Identification of new molecules effective • CreativeESCMID synthesis and assay methods eLibrary • In vitro and in vivo efficacy © by author Collections of Bacteria (BSL1-BSL-3) • Mycobacterium tuberculosis (H37Rv from BEI) • Mycobacterium avium Subsp. paratuberculosis • Drug resistant Mycobacterium tuberculosis (ATCC 27294) • Rifampicin resistant Mycobacterium tuberculosis STRAIN TMC 331(ATCC 35838) • Isoniazid resistant Mycobacterium tuberculosis STRAIN TMC 303(ATCC 35822) • Mycobacterium smegmatis (ATCC 607™) • Mycobacterium smegmatis (ATCC14468™) • Mycobacterium bovis BCG • Staphylococcus aureus. Subsp. Aureus (ATCC 25923) • Staphylococcus epidermidis Evans (ATCC® 35984™) • Staphylococcus aureus subsp. aureus Rosenbach (ATCC® 25923™) • Enterococcus faecalis (ATCC 19433™) • Enterococcus faecalis carrying pam373 (ATCC43062) • Streptococcus salivarius (ATCC 7073) • Streptococcus pneumoniae (ATCC 6301) • MRSA BAA-2094 • MRSA BAA-41 Regional Biocontainment • Staphylococcus aureus subsp. aureus (BAA-44) • Staphylococcus aureus subsp. aureus (ATCC-33592) Laboratory (RBL) at UTHSC • Staphylococcus aureus, STRAIN M10/0148 (BAA-2313) • Staphylococcus aureus (BAA-1683) • Clostridium difficile (ATCC 43596) • Staphylococcus aureus (BAA-42) • Clostridium perfringens (ATCC13124) • Staphylococcus aureus (ATCC6538) • Lactobacillus casei (Orla-Jensen) Hansen and Lessel (ATCC 393™) • Enterococcus faecium (ATCC 349) • Lactobacillus acidophilus (Moro) Hansen and Mocquot (ATCC 4356™) • Enterococcus durans (ATCC 6056) • Bifidobacterium longum subsp. longum Reuter (ATCC 15707™) • Enterococcus hirae (ATCC 49135) • Eggerthella lenta (Eggerth) (ATCC 43055™) • Bacillus cereus (No 2045) • Bacillus subtilis subsp. subtilis (Ehrenberg) Cohn (ATCC 6051) • Bacillus cereus (FERM BP-01719) • Streptomyces aurantiacus (ATCC19822™) • Bacteroides fragilis (ATCC 25285) • E. coli (ATCC 10798) • Fusobacterium peridonticum (ATCC 33693) ESCMID• E. coli (ATCC 35218) eLibrary • E. coli (Migula) Castellani and Chalmers (ATCC 10798™) • Pseudomonas aeruginosa (ATCC 27853™) • Klebsiella pneumoniae subsp. Pneumonia (ATCC 8047™) • Acinetobacter baumannii (ATCC 19606) Antimicrobial Susceptibility Tests • MDR Acinetobacter © baumannii by (ATCC BAA -1800)author Antimycobacterial Pleuromutilin Analogues UT-800 Efficacy against dormant Mtb Efficacy against intracellular Mtb (Wayne mode) Mycobacterium tuberculosis UT-800 ESCMID eLibraryFluorescence confocal microscopy of J774A.1 murine macrophages infected with tdTomato (red) expressing Mtb after the treatment of the mlecules (at 4xMIC). Fixed cells were stained with DAPI (4',6-diamidino-2- © by authorphenylindole) to visualize nuclei. Spectrum of Activity against Gram-negative Bacteria K. pneumoniae K. pneumoniae K. pneumoniae E. coli E. coli PCI 602 GN69 GN4081 BE1121 JR66/W677 (TC, CM, SM, KM, APC) (tolC mdtK) Meropenem 0.25 8.0 0.031 0.031 0.031 UT-490 0.25 32.0 64.0 0.25 8.00 P. aeruginosa P. aeruginosa P. aeruginosa P. aeruginosa A3 GN17433 K-Ps102 GN17433 Meropenem 1.0 0.25 4.0 0.25 UT-490 64.0 32.0 >64.0 32.0 A. baumannii A. baumannii A. baumannii A. baumannii ATCC19606 JCM6841 ATCC BAA-1710 ATCC BAA-1800 (MDR) (MDR) Meropenem 2.0 2.0 1.0 8.0 UT-490 6.25 2.0 6.25 6.25-12.5 ESCMID eLibrary Acinetobacter baumannii UT-490 (ATCC19606) © by author Pleuromutilin • Pleuromutilin was first isolated in 1952 from two Basidiomycete spp. (Pleurotus mutilus and Pleurotus passeckerianus) • Tiamulin and Valunemulin, were successfully developed as therapeutic agents for veterinary use • Retapamulin (GSK) is the first antibacterial agent of the pleuromutilin class, approved in 2007 by FDA for the topical treatment, mainly caused by the Gram-positive Pleuromutilin bacteria (S. aureus and S. pyogenes) • BC-3781 (Nabriva Therapeutics) entered Phase II clinical studies, demonstrating a therapeutic potential for the treatment of skin infections and lung including community-acquired bacterial pneumonia (systemic) Pleurotus mutilus MycoBank # 168967 Published in 1876 ESCMID eLibrary © by author Mode of Action of Pleuromutilin Pleuromutilins 1. Activation - Formation of 7. Termination – Release of amino acyl tRNA Linez_ olid polypeptide chain _ AA _ _ _ 5. Elongation – Peptidyl_ transfer Aminogly_ cosides _ _ _ _ 6. Elonga_ tion – 50S Translocation 5 0 PDB IDs 3g4s and 5v7q overlaid by using UCSF 3. Elongation – Entry of S aminoacyl tRNA Chimera software (The binding site: about 10 Å) A A e – S m n t so tio co o o a g S d p ib ng in 30 o AA R lo ad n E e 3 . f r 0 4 oo S Pr t S r 0 a n 5 t o S d o S c 0 3 A N R m RNAP S 0 3 5` 2. Initiation – 30S ribosomal subunit binds to mRNA ESCMID eLibrary Binding sites of pleuromutilin derivatives and linezolid on bacterial 50s ribosome. © byPleuromutilin author derivatives interfere with both the A- and P- sites Cross-resistance to LinedzolidR-strains? UT-490 MIC100 0.024 mg/mL against S. aureus ATCC 6538 MIC100 6.25 mg/mL against A. baumannii ATCC 19606 UT-490R-S. aureus ATCC 6538 (MIC 20 mg/mL) UT-490R-A. baumannii ATCC 19606 (MIC 100 mg/mL) Concentrations of UT-490 6.25 mg/mL 12.5 mg/mL 25.0 mg/mL LinezolidR-A. baumannii ATCC 19606 0 0 0 Number of colonies Concentrations of UT-490 1.0 mg/mL 5.0 mg/mL 10.0 mg/mL LinezolidR-S. aureus ATCC 6538 0 0 0 Number of colonies Linezolid MIC <1.0 g/mL against S. aureus ATCC 6538 ESCMID100 m eLibraryConclusion: MIC50 50 mg/mL against A. baumannii ATCC 19606 A mechanism of resistance of two strains against linezolid and UT-490 is different, although both share LinezolidR-S. aureus ATCC 6538 (MIC 20 mg/mL) LinezolidR-A. baumannii ATCC 19606 (MIC >500 mg/mL) the binding domain of the A-site partially, and cross © by authorresistance may not happen. Systemic Application of Pleuromutilin? Half-life (t1/2) in the rat liver microsomes 2500 Retapamulin-H2 2000 1500 Retapamulin 1000 Concentration (ng/mL) Concentration 500 0 0 20 40 60 80 100 ESCMID eLibraryTime (min) © by author Systemic Application of Pleuromutilin? Half-life (t1/2) in the rat liver microsomes 100 90 80 70 60 UT-490 50 40 30 Concentration (ng/mL) Concentration 20 UT-490 10 Valunemulin 0 0 10 20 30 40 50 60 Time (min) Cytotoxicity against Vero cells 1.2 1 1 Valnemulin 0.8 Valunemulin 0.6 0.4 UT-490 ESCMID (570nm) Absorbance eLibrary 0.2 Valunemulin 0 0 50 100 150 200 © by authorConcentration (mg/mL) Systemic Application of Pleuromutilin? Half-life (t1/2) in the rat liver microsomes UT-800 UT-810 ESCMIDUT-815 eLibrary © by author Systemic Application of Pleuromutilin? Half-life (t1/2) in the rat liver microsomes UT-800 UT-810 ESCMIDUT-815 eLibrary © by author In vitro Cytotoxicity of Pleuromutilin Analogues Cytotoxicity of selected analogues against Vero cells UT-490 Rifampicin Valunemulin UT-490 UT-800 Other UT-analogues Valnemulin IC50 45-50 mg/mL (UT-490), UT-810 IC50 15-35 mg/mL (UT-800, 810, 815, and several others), IC 15 g/mL (Valnemulin) ESCMID50 meLibrary Hemolysis 0% at 200 mg/mL concentration (UT-490) UT-815 © >50%by at 10 m g/mLauthor concentration (tunicamycin)
Load more

Recommended publications
  • What Is the Best Treatment for Impetigo?
    Evidence-based answers from the Family Physicians Inquiries Network clinical inquiries Jae Shim, MD; Jeffrey Lanier, MD What is the best treatment Martin Army Community Hospital, Fort Benning, Ga for impetigo? Maylene (Kefeng) Qui, MLIS Biomedical Library, University of Pennsylvania, EvidEncE-basEd answEr Philadelphia AssistAnt EDItOR Although evidence is lack- als [RCTs] and a single RCT of retapamulin). Paul Crawford, MD A ing to support a single best treat- Topical bacitracin and fusidic acid are Nellis Family Medicine ment for impetigo, topical mupirocin, 15% more likely than disinfectant solu- Residency, Nellis Air Force Base, Nev fusidic acid, gentamicin, and retapamu- tions to cure or improve impetigo (SOR: a, lin are all at least 20% more likely than systematic review of RCTs). The opinions and assertions con- tained herein are the private views placebo to produce cure or improvement Oral antibiotics may be as effective as of the authors and are not to be (strength of recommendation [SOR]: a, topical antibiotics (SOR: b, RCTs with dif- construed as official or as reflecting the views of the US Army or the meta-analysis of randomized controlled tri- ferent results). Department of Defense. Evidence summary A 2012 Cochrane review of various inter- Most data on the effectiveness of topical an- ventions included 68 RCTs with a total of 5708 tibiotics focus on bacitracin, fusidic acid (not participants, primarily from pediatric or der- available in the United States), and mupiro- matology hospital outpatient clinics in North cin. Retapamulin
    [Show full text]
  • Antibiotics Acting on the Translational Machinery
    Cell Science at a Glance 1391 Antibiotics acting on ribosomal factors, and recent structural Initiation studies of the ribosome (Ban et al., 2000; Prokaryotic protein synthesis starts with the translational Harms et al., 2001; Nissen et al., 2000; the formation of an initiation complex machinery Schlünzen et al., 2000; Wimberly et al., comprising the mRNA, initiator tRNA fMet 1, 1 2000; Yusupov et al., 2001) and (fMet-tRNA ), three initiation factors Jörg M. Harms *, Heike Bartels , complexes of ribosomes with inhibitors (IFs) and the 30S subunit. IF3 binding Frank Schlünzen1 and Ada (Brodersen et al., 2000; Pioletti et al., prevents association of the two Yonath1,2 2001; Schlünzen et al., 2001; Hansen et ribosomal subunits, verifies codon- 1Max-Planck Arbeitsgruppe Ribosomenstruktur, al., 2002; Bashan et al., 2003; Schlünzen anticodon complementarity and appears Notkestr. 85, 22607 Hamburg, Germany 2Department of Structural Biology, Weizmann et al., 2003) are now revealing the to regulate positioning of the mRNA. Institute, 76100 Rehovot, Israel mechanisms underlying their inhibitory IF1 blocks the acceptor site (A-site) to *Author for correspondence (e-mail: activity. prevent premature binding of the A-site [email protected]) tRNA. After binding of fMet-tRNAfMet, IF3 is released; this triggers hydrolysis Journal of Cell Science 116, 1391-1393 Responsibility for the various steps of © 2003 The Company of Biologists Ltd polypeptide synthesis is divided among of IF2-bound GTP, and IF2 and IF1 are doi:10.1242/jcs.00365 released (the exact sequence of events is the two ribosomal subunits (30S and not known). The 50S subunit then joins 50S). The 30S subunit ensures fidelity of Despite the appearance of bacterial the 30S initiation complex, forming the strains resistant to all clinical antibiotics, decoding by establishing accurate 70S ribosome.
    [Show full text]
  • In Vitro Activity of Retapamulin
    Correspondence: Abstract 2338 B. Johnson In Vitro Activity of Retapamulin (SB-275833), a Novel Topical Antimicrobial, against 3721 Gram-Positive IHMA (F-2050) 2122 Palmer Drive Schaumburg Isolates Associated with Skin and Skin Structure Infections (SSSIs) From 17 Sites in North America IL 60173 USA 1 1 1 1 2 2 1 1 Tel: +1 847 303 5003 B. Johnson, A. Jordan, S. Bouchillon, D. Hoban, N. Scangarella, R. Shawar, J. Johnson & R. Badal Fax: +1 847 303 5601 1International Health Management Associates, Schaumburg, IL, USA; 2GlaxoSmithKline, Collegeville, PA, USA E-mail: [email protected] Table 3. MIC (µg/mL) Summary for Retapamulin and Comparators against S. aureus from Table 6. MIC (µg/mL) Summary For Retapamulin and Comparators against Viridans Revised Abstract Materials and Methods North America (n = 1182) Streptococci from North America (n = 471) Background: Retapamulin is a novel pleuromutilin currently in development as a topical G MIC endpoints were determined by broth microdilution according to MIC (µg/mL) MIC (µg/mL) antimicrobial for the treatment of skin and skin structure infections (SSSIs) that shows no Clinical and Laboratory Standards Institute (CLSI) guidelines3 for retapamulin a a Compound %Sus %Int %Res Range MIC50 MIC90 Compound %Sus %Int %Res Range MIC50 MIC90 target specific cross-resistance to other classes of antibiotics and exhibits a unique mode of and 14 comparators in customized dried broth microdilution panels (Trek action. Methods: A total of 3721 clinical isolates of staphylococci (Staphylococcus aureus and Retapamulin NA NA NA 0.015–0.5 0.06 0.12 Retapamulin NA NA NA 0.004–0.5 0.06 0.25 Diagnostic Systems Ltd, West Sussex, UK).
    [Show full text]
  • Topical Antibiotics for Impetigo: a Review of the Clinical Effectiveness and Guidelines
    CADTH RAPID RESPONSE REPORT: SUMMARY WITH CRITICAL APPRAISAL Topical Antibiotics for Impetigo: A Review of the Clinical Effectiveness and Guidelines Service Line: Rapid Response Service Version: 1.0 Publication Date: February 21, 2017 Report Length: 23 Pages Authors: Rob Edge, Charlene Argáez Cite As: Topical antibiotics for impetigo: a review of the clinical effectiveness and guidelines. Ottawa: CADTH; 2017 Feb. (CADTH rapid response report: summary with critical appraisal). ISSN: 1922-8147 (online) Disclaimer: The information in this document is intended to help Canadian health care decision-makers, health care professionals, health systems leaders, and policy-makers make well-informed decisions and thereby improve the quality of health care services. While patients and others may access this document, the document is made available for informational purposes only and no representations or warranties are made with respect to its fitness for any particular purpose. The information in this document should not be used as a substitute for professional medical advice or as a substitute for the application of clinical judgment in respect of the care of a particular patient or other professional judgment in any decision-making process. The Canadian Agency for Drugs and Technologies in Health (CADTH) does not endorse any information, drugs, therapies, treatments, products, processes, or services. While care has been taken to ensure that the information prepared by CADTH in this document is accurate, complete, and up-to-date as at the applicable date the material was first published by CADTH, CADTH does not make any guarantees to that effect. CADTH does not guarantee and is not responsible for the quality, currency, propriety, accuracy, or reasonableness of any statements, information, or conclusions contained in any third-party materials used in preparing this document.
    [Show full text]
  • ALTABAX (Retapamulin)
    HIGHLIGHTS OF PRESCRIBING INFORMATION --------------------- DOSAGE FORMS AND STRENGTHS -------------- These highlights do not include all the information needed to use 10 mg retapamulin/1g of ointment in 15-, and 30-gram tubes (3) ALTABAX safely and effectively. See full prescribing information for -------------------------------CONTRAINDICATIONS------------------------ ALTABAX. None. (4) ® ----------------------- WARNINGS AND PRECAUTIONS ---------------- ALTABAX (retapamulin ointment), 1% Discontinue in the event of sensitization or severe local irritation. (5.1) For Dermatological use only Not intended for ingestion. Not for intraoral, intranasal, ophthalmic, or Initial U.S. Approval: 2007 intravaginal use. (5.2) ----------------------------INDICATIONS AND USAGE--------------------- ------------------------------ ADVERSE REACTIONS ----------------------- ALTABAX, a pleuromutilin antibacterial, is indicated for the topical The most common drug-related adverse reaction was application site irritation treatment of impetigo due to Staphylococcus aureus (methicillin-susceptible (≤2% of patients). (6) isolates only) or Streptococcus pyogenes in patients aged 9 months or older. (1) Safety in patients younger than 9 months has not been established. To report SUSPECTED ADVERSE REACTIONS, contact ----------------------- DOSAGE AND ADMINISTRATION ---------------- GlaxoSmithKline at 1-888-825-5249 or FDA at 1-800-FDA-1088 or Apply a thin layer of ALTABAX to the affected area (up to 100 cm2 in www.fda.gov/medwatch. total area in adults or 2%
    [Show full text]
  • Swedres-Svarm 2019
    2019 SWEDRES|SVARM Sales of antibiotics and occurrence of antibiotic resistance in Sweden 2 SWEDRES |SVARM 2019 A report on Swedish Antibiotic Sales and Resistance in Human Medicine (Swedres) and Swedish Veterinary Antibiotic Resistance Monitoring (Svarm) Published by: Public Health Agency of Sweden and National Veterinary Institute Editors: Olov Aspevall and Vendela Wiener, Public Health Agency of Sweden Oskar Nilsson and Märit Pringle, National Veterinary Institute Addresses: The Public Health Agency of Sweden Solna. SE-171 82 Solna, Sweden Östersund. Box 505, SE-831 26 Östersund, Sweden Phone: +46 (0) 10 205 20 00 Fax: +46 (0) 8 32 83 30 E-mail: [email protected] www.folkhalsomyndigheten.se National Veterinary Institute SE-751 89 Uppsala, Sweden Phone: +46 (0) 18 67 40 00 Fax: +46 (0) 18 30 91 62 E-mail: [email protected] www.sva.se Text, tables and figures may be cited and reprinted only with reference to this report. Images, photographs and illustrations are protected by copyright. Suggested citation: Swedres-Svarm 2019. Sales of antibiotics and occurrence of resistance in Sweden. Solna/Uppsala ISSN1650-6332 ISSN 1650-6332 Article no. 19088 This title and previous Swedres and Svarm reports are available for downloading at www.folkhalsomyndigheten.se/ Scan the QR code to open Swedres-Svarm 2019 as a pdf in publicerat-material/ or at www.sva.se/swedres-svarm/ your mobile device, for reading and sharing. Use the camera in you’re mobile device or download a free Layout: Dsign Grafisk Form, Helen Eriksson AB QR code reader such as i-nigma in the App Store for Apple Print: Taberg Media Group, Taberg 2020 devices or in Google Play.
    [Show full text]
  • NEW ANTIBACTERIAL DRUGS Drug Pipeline for Gram-Positive Bacteria
    NEW ANTIBACTERIAL DRUGS Drug pipeline for Gram-positive bacteria Françoise Van Bambeke, PharmD, PhD Paul M. Tulkens, MD, PhD Pharmacologie cellulaire et moléculaire Louvain Drug Research Institute, Université catholique de Louvain, Brussels, Belgium http://www.facm.ucl.ac.be Based largely on presentations given at the 24th and 25th European Congress of Clinical Microbiology and Infectious Diseases and the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy 22/05/2015 Gause Institute for New Antibiotics: the anti-Gram positive pipeline 1 Disclosures Research grants for work on investigational compounds discussed in this presentation from • Cempra Pharmaceuticals • Cerexa • GSK • Melinta therapeutics • The Medicine Company • MerLion Pharmaceuticals • Theravance • Trius 22/05/2015 Gause Institute for New Antibiotics: the anti-Gram positive pipeline 2 Belgium 22/05/2015 Gause Institute for New Antibiotics: the anti-Gram positive pipeline 3 Belgium 10 millions inhabitants … 10 Nobel prizes (10/850) • Peace - Institute of International Law, Ghent (1904) - Auguste Beernaert (1909) - Henri Lafontaine (1913) - Father Dominique Pire (1958) • Literature - Maurice Maeterlinck, Ghent (1911) • Medicine - Jules Bordet, Brussels (1919) - Corneille Heymans, Ghent (1938) - Christian de Duve, Louvain (1974) - Albert Claude, Brussels (1974) • Chemistry - Ilya Prigogyne, Brussels (1977) - Physics - François Englert, Brussels (2013) 22/05/2015 Gause Institute for New Antibiotics: the anti-Gram positive pipeline 4 The Catholic University of Louvain in brief (1 of 4) • originally founded in 1425 in the city of Louvain (in French and English; known as Leuven in Flemish) 22/05/2015 Gause Institute for New Antibiotics: the anti-Gram positive pipeline 5 The Catholic University of Louvain in brief (2 of 4) • It was one of the major University of the so-called "Low Countries" in the 1500 – 1800 period, with famous scholars and discoverers (Vesalius for anatomy, Erasmus for philosophy, …).
    [Show full text]
  • New Antibiotics for the Treatment of Acute Bacterial Skin and Soft Tissue Infections in Pediatrics
    pharmaceuticals Review New Antibiotics for the Treatment of Acute Bacterial Skin and Soft Tissue Infections in Pediatrics Nicola Principi 1, Alberto Argentiero 2, Cosimo Neglia 2, Andrea Gramegna 3,4 and Susanna Esposito 2,* 1 Università degli Studi di Milano, 20122 Milan, Italy; [email protected] 2 Pediatric Clinic, Pietro Barilla Children’s Hospital, Department of Medicine and Surgery, University of Parma, 43121 Parma, Italy; [email protected] (A.A.); [email protected] (C.N.) 3 Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Internal Medicine Department, Respiratory Unit and Cystic Fibrosis Adult Center, 20122 Milan, Italy; [email protected] 4 Department of Pathophysiology and Transplantation, University of Milan, 20122 Milan, Italy * Correspondence: [email protected]; Tel.: +39-052-190-3524 Received: 29 September 2020; Accepted: 19 October 2020; Published: 23 October 2020 Abstract: Acute bacterial skin and soft tissue infections (aSSTIs) are a large group of diseases that can involve exclusively the skin or also the underlying subcutaneous tissues, fascia, or muscles. Despite differences in the localization and severity, all these diseases are due mainly to Gram-positive bacteria, especially Staphylococcus aureus and Streptococcus pyogenes. aSSTI incidence increased considerably in the early years of this century due to the emergence and diffusion of community-acquired methicillin-resistant S. aureus (CA-MRSA). Despite the availability of antibiotics effective against CA-MRSA, problems of resistance to these drugs and risks of significant adverse events have emerged. In this paper, the present knowledge on the potential role new antibiotics for the treatment of pediatric aSSTIs is discussed. The most recent molecules that have been licensed for the treatment of aSSTIs include ozenoxacin (OZ), ceftaroline fosamil (CF), dalbavancin (DA), oritavancin (OR), tedizolid (TD), delafloxacin (DL), and omadacycline (OM).
    [Show full text]
  • New Drugs of 2007 by Amy P
    CONTINUING EDUCATION New Drugs of 2007 By Amy P. Witte, PharmD; Jodie V. Mahlhotra, PharmD; and Trevor McKibbin, PharmD, MSc, BCPS pon successful completion of this There have been no reported contraindications with article, the pharmacist should be the use of retapamulin. A thin layer should be applied to able to: the affected area (up to 100 cm2 in total area in adults or 1. Identify the new molecular entities 2 percent total body surface area in pediatric patients) approved by the Food and Drug twice daily for five days. Administration (FDA) in 2007. The most common adverse effect seen with re- U2. Review approved indications, mechanism of tapamulin use was application site irritation. Patients action, and pharmacokinetic profile for each should discontinue the use of retapamulin in the event agent. of severe local irritation or sensitization. It is not intend- 3. List the available dosage forms and ed for ingestion or for intraoral, intranasal, ophthalmic, strengths, dosing schedules, and routes of or intravaginal use. Patients should also be aware of administration for the new agents. the potential for microbial overgrowth while using reta- 4. Describe the potential adverse effects, drug pamulin. If a superinfection is suspected during treat- interactions, precautions, and contraindica- ment, the patient should contact their physician. The tions associated with routine use. effect of retapamulin in combination with other topical 5. Identify medications that have been with- agents to the same area of skin has not been studied. drawn from the market in 2007. Retapamulin is a pregnancy category B agent. How- ever, it is not known whether retapamulin is excreted In 2007, the FDA approved 15 new molecular in breast milk.
    [Show full text]
  • Writer Master Template
    Nabriva Therapeutics AG Clinical Protocol NAB-BC-3781-3102 Clinical Protocol No. NAB-BC-3781-3102 A Phase 3, Randomized, Double-Blind, Double-Dummy Study to Compare the Efficacy and Safety of Oral Lefamulin (BC-3781) Versus Oral Moxifloxacin in Adults With Community-Acquired Bacterial Pneumonia US IND 125546 (Oral) EudraCT Number 2015-004782-92 Protocol Status Version Date Original 1.0 21-Dec-2015 Amendment 1 2.0 17-Feb-2016 Amendment 2 3.0 17-Mar-2016 The information contained herein is the property of Nabriva Therapeutics AG and may not be produced, published, or disclosed to others without written authorization of Nabriva Therapeutics AG. V3.0: 17-Mar-2016 Page 1 of 102 Confidential Information Nabriva Therapeutics AG Clinical Protocol NAB-BC-3781-3102 SPONSOR RELATED CONTACT DETAILS A Phase 3, Randomized, Double-Blind, Double-Dummy Study to Compare the Efficacy and Safety of Oral Lefamulin (BC-3781) Versus Oral Moxifloxacin in Adults With Community-Acquired Bacterial Pneumonia (Protocol NAB-BC-3781-3102 with Amendments 1 and 2) Sponsor: Nabriva Therapeutics AG Leberstraße 20 1110 Vienna Austria Sponsor’s Study Managers: Patricia Spera, PhD Nabriva Therapeutics US, Inc. 1000 Continental Drive, Suite 600 King of Prussia, PA 19406 USA Tel: +1 610 816 6656 Cell: +1 610 209 5574 Email: [email protected] Claudia Lell, PhD Nabriva Therapeutics AG Leberstraße 20 1110 Vienna Austria Tel: +43 1 74093 1242 Cell: +43 664 9631469 Email: [email protected] Sponsor’s Medical Officer: Leanne Gasink, MD Senior Director, Clinical Development and Medical Affairs Nabriva Therapeutics AG Nabriva Therapeutics US, Inc.
    [Show full text]
  • Characterization of a Novel Gene, Srpa, Conferring Resistance to Streptogramin A, 2 Pleuromutilins, and Lincosamides in Streptococcus Suis1
    bioRxiv preprint doi: https://doi.org/10.1101/2020.08.07.241059; this version posted August 7, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. 1 Characterization of a novel gene, srpA, conferring resistance to streptogramin A, 2 pleuromutilins, and lincosamides in Streptococcus suis1 3 Chaoyang Zhang,a Lu Liu,a Peng Zhang,a Jingpo Cui,a Xiaoxia Qin, a Lichao Ma,a Kun Han,a 4 Zhanhui Wang b, Shaolin Wang b, Shuangyang Ding b, Zhangqi Shen a,b 5 6 a Beijing Advanced Innovation Center for Food Nutrition and Human Health, College of Veterinary 7 Medicine, China Agricultural University, Beijing, China. 8 b Beijing Key Laboratory of Detection Technology for Animal-Derived Food Safety and Beijing 9 Laboratory for Food Quality and Safety, China Agricultural University, Beijing, China 10 11 Address correspondence to Zhangqi Shen, [email protected]; 12 13 14 15 1 Abbreviations: Multidrug-resistant (MDR), methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant Enterococcus faecium (VRE), peptidyl-transferase center (PTC), transmembrane domains (TMDs), valnemulin (VAL), enrofloxacin (ENR), fluorescence polarization immunoassay (FPIA), nucleotide-binding sites (NBSs), fluorescence polarization (FP), carbonyl cyanide m- chlorophenylhydrazone (CCCP) bioRxiv preprint doi: https://doi.org/10.1101/2020.08.07.241059; this version posted August 7, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. 16 Abstract 17 Antimicrobial resistance is undoubtedly one of the greatest global health threats.
    [Show full text]
  • Third ESVAC Report
    Sales of veterinary antimicrobial agents in 25 EU/EEA countries in 2011 Third ESVAC report An agency of the European Union The mission of the European Medicines Agency is to foster scientific excellence in the evaluation and supervision of medicines, for the benefit of public and animal health. Legal role Guiding principles The European Medicines Agency is the European Union • We are strongly committed to public and animal (EU) body responsible for coordinating the existing health. scientific resources put at its disposal by Member States • We make independent recommendations based on for the evaluation, supervision and pharmacovigilance scientific evidence, using state-of-the-art knowledge of medicinal products. and expertise in our field. • We support research and innovation to stimulate the The Agency provides the Member States and the development of better medicines. institutions of the EU the best-possible scientific advice on any question relating to the evaluation of the quality, • We value the contribution of our partners and stake- safety and efficacy of medicinal products for human or holders to our work. veterinary use referred to it in accordance with the • We assure continual improvement of our processes provisions of EU legislation relating to medicinal prod- and procedures, in accordance with recognised quality ucts. standards. • We adhere to high standards of professional and Principal activities personal integrity. Working with the Member States and the European • We communicate in an open, transparent manner Commission as partners in a European medicines with all of our partners, stakeholders and colleagues. network, the European Medicines Agency: • We promote the well-being, motivation and ongoing professional development of every member of the • provides independent, science-based recommenda- Agency.
    [Show full text]